Will Avanir drug OK spark takeover attempt?

Shares of Avanir Pharmaceuticals (AVNR) soared 112 percent as news spread that the FDA has approved Nuedexta, the first treatment for pseudobulbar affect, or involuntary emotional expression syndrome. Peak sales for the new drug are projected to hit $350 million to $500 million and some analysts quickly began buzzing about a potential takeover in the wake of an approval.

The approval marks a major success for Avanir, which had to go back to the drawing board four years ago after the FDA told the developer that it was worried about the potential impact of one of the chemical ingredients in the therapy. Investigators then cut the dose level of quinidine by a third and reported more than a year ago that the new formulation of Nuedexta, once called Zenvia, met the primary endpoint in a new trial.

More than two million people with neurological conditions like Lou Gehrig's disease and Alzheimer's suffer from involuntary emotional outbursts, crying and laughing jags that occur with no warning. "We like to refer to PBA as one of the most common diseases that people have never heard of,'' Avanir CEO Keith Katkin told the New York Times.

Reuters story raised the prospect of a potential takeover, noting that pharma companies have been prowling the globe for new drugs like Nuedexta.

- check out the story from Reuters
- and read the NYT report

Suggested Articles

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.

At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.